GLIOMATHERAPY. Inmunoterapia con un anticuerpo monoclonalfrente a tumores de cerebro de alto grado
Dr. Angel Ayuso
Ministerio de Economía y Competitividad. Programa Estatal de Investigación, Desarrollo e Innovación Orientada a los Retos de la Sociedad 2013-2016. RTC-2015-3846-1
Duration: 2015 - 2018
Malignant gliomas are the most common primary brain tumours and account for the majority of cancers in the adult central nervous system, and the most aggressive and frequent (60%–70%) glioma subtype is glioblastoma multiforme (GBM). Current glioma treatments based on surgery, radiation, and chemotherapy show little success, with a median survival of only 14.6 months. One of the underlying reasons for this treatment failure is the presence of cancer stem cells (CSC) that initiate and maintain the tumour mass and are responsible of recurrences. Recently, we have demonstrated that Nilo1 (a monoclonal antibody) identify CSCs from human GBM samples. This antibody is also able to inhibit neurosphere proliferation in vitro. All together suggests that Nilo 1 might be useful to define new therapeutic approaches to fight human gliomas. With this project, IMDEA nanoscience, in collaboration with Althia Health SL, and the CSC´s lab at CIB-CSIC, aims to determine the role of Nilo 1 in human brain tumour diagnostic and treatment, by using both in vitro 3D CSCs cultures and in vivo mice xenotransplanted with human-derived CSCs models.